Clinical trials: Immunoglobulin
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Study of CS1001 in Subjects with Advanced Solid Tumors
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
- Trial name
- NCT03744403
- Testing
- CS1001
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- CStone Pharmaceuticals
HIV Infections
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
People infected with HIV may have low levels of the virus in their body, even if they are taking HIV medications. This study will evaluate the safety, pharmacokinetics (PK) (which is how the body interacts with drugs), and immune…
- Trial name
- NCT02028403
- Testing
- BMS-936559
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Inflammation, Vasculitis
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
This study will collect fluid and tissue samples from the bronchi (air passages to the lungs) of patients with Wegener's granulomatosis for laboratory examination.
- Conditions
- Inflammation, Vasculitis, Wegener's Granulomatosis
- Trial name
- NCT00001541
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Trial name
- NCT00007995
- Testing
- filgrastim, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Recurrent or Metastatic Head and Neck Carcinoma
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT07686588
- Testing
- Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
- Volunteers
- 20 people
- Sponsor
- Biying Chen
Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and…
- Trial name
- EDGE-Gastric (NCT05329766)
- Testing
- Domvanalimab, Quemliclustat, Zimberelimab
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 332 people
- Sponsor
- Arcus Biosciences, Inc.
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
Pertussis
3-year Follow-up After a Single Dose Acellular Pertussis Vaccination
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd.
- Trial name
- NCT04102137
- Testing
- Pertagen (aP BioNet), Boostagen (TDaP BioNet), Adacel
- Where
- Thailand
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Rheumatoid Arthritis
Phase 2 AMG 714 in Rheumatoid Arthritis
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.
- Trial name
- NCT00433875
- Testing
- AMG 714
- Volunteers
- 180 people
- Sponsor
- Amgen
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00513266
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- 4 sites in Switzerland
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Covid19
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.
- Trial name
- B-EPIC (NCT04796402)
- Testing
- Bamlanivimab, Standard of Care
- Where
- Canada
- Volunteers
- 576 people
- Sponsor
- Fraser Health
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma, GEJ Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with PD-1 inhibitors as first-line maintenance therapy for advanced HER-2 Negative Gastric Cancer.
- Conditions
- Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy
- Trial name
- NCT06888037
- Testing
- Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）, Maintenance treatment (after 3 months): fruquintinib+PD-1
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.
- Trial name
- NCT00195039
- Testing
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
COVID-19
Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups
Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy.
- Trial name
- NCT05827939
- Testing
- Covid19 Vaccination dose
- Where
- Taiwan
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Psoriasis Arthritis
A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as…
- Trial name
- STRIDE-PsA (NCT07417995)
- Testing
- Biologic or targeted synthetic DMARD (b/tsDMARD)
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Royal United Hospitals Bath NHS Foundation Trust
Japanese Encephalitis Vaccine
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules.
- Trial name
- NCT06825312
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated, Japanese Encephalitis Vaccine, Live
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04092283
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 830 sites in United States, Guam
- Volunteers
- 660 people
- Sponsor
- National Cancer Institute (NCI)
Immune System Diseases, Premature Infant Disease
Oral Colostrum and Its Effect on Immune System
The purpose of this project is to increase the serum immunological defenses of premature infants less then 32 weeks of gestation by administrating colostrum in the oropharyngeal mucosa versus placebo
- Conditions
- Immune System Diseases, Premature Infant Disease, Immunoglobulin Deficiency
- Trial name
- NCT03578341
- Testing
- Orally Colostrum
- Where
- 2 sites in Mexico
- Volunteers
- 96 people
- Sponsor
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.